Dosing and Administration

Dosing Schedule 1

Administer ALECENSA® (alectinib) until disease progression or unacceptable toxicity. 1

  • The recommended dose of ALECENSA is 600 mg orally twice daily with food 1
    • The recommended dose of ALECENSA in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily
  • Do not open or dissolve the contents of the capsule 1
  • If a dose of ALECENSA is missed or vomiting occurs after taking a dose of ALECENSA, take the next dose at the scheduled time 1

Monitoring 1

Liver Monitoring:

  • Monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations

Lung Monitoring:

  • Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, and fever)

Kidney Monitoring:

  • Withhold treatment for severe renal impairment, then resume treatment at a reduced dose, or permanently discontinue

Heart Monitoring:

  • Monitor heart rate and blood pressure regularly

CPK Monitoring:

  • Assess CPK levels every 2 weeks during the first month of treatment and as clinically indicated in patients reporting any unexplained muscle pain, tenderness, or weakness

For more information on ALECENSA dosing, download the ALECENSA Dosing and Administration Guide.

1L=first-line; ALT=alanine transaminase; AST=aspartate transaminase; CPK=creatine phosphokinase; ILD=interstitial lung disease; PFS=progression-free survival.

1L PFS Results

View PFS results vs crizotinib from the head-to-head ALEX trial.

1L Safety Profile

Learn about the 1L safety profile with ALECENSA.

Contact a Representative

Contact your local Genentech representative for more information about ALECENSA.